Sokol V Todi Selected Research

Machado-Joseph Disease (Spinocerebellar Ataxia Type 3)

12/2021	Targeting the VCP-binding motif of ataxin-3 improves phenotypes in Drosophila models of Spinocerebellar Ataxia Type 3.
11/2020	The Deubiquitinating Enzyme Ataxin-3 Regulates Ciliogenesis and Phagocytosis in the Retina.
10/2020	Degron capability of the hydrophobic C-terminus of the polyglutamine disease protein, ataxin-3.
1/2020	Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein.
1/2020	Ubiquitin-interacting motifs of ataxin-3 regulate its polyglutamine toxicity through Hsc70-4-dependent aggregation.
12/2019	Differential toxicity of ataxin-3 isoforms in Drosophila models of Spinocerebellar Ataxia Type 3.
1/2018	Toxicity and aggregation of the polyglutamine disease protein, ataxin-3 is regulated by its binding to VCP/p97 in Drosophila melanogaster.
1/2017	Interaction of the polyglutamine protein ataxin-3 with Rad23 regulates toxicity in Drosophila models of Spinocerebellar Ataxia Type 3.
11/2016	Unbiased screen identifies aripiprazole as a modulator of abundance of the polyglutamine disease protein, ataxin-3.
10/2015	The deubiquitinase ataxin-3 requires Rad23 and DnaJ-1 for its neuroprotective role in Drosophila melanogaster.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sokol V Todi Research Topics

Disease

15	Machado-Joseph Disease (Spinocerebellar Ataxia Type 3) 12/2021 - 10/2007
13	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 10/2007
7	Spinocerebellar Ataxias (Spinocerebellar Ataxia) 01/2022 - 08/2014
4	Ataxia (Dyssynergia) 01/2022 - 08/2014
4	Parkinson Disease (Parkinson's Disease) 12/2019 - 09/2014
3	Huntington Disease (Huntington's Disease) 01/2021 - 09/2014
2	X-Linked Bulbo-Spinal Atrophy 01/2021 - 01/2018
2	Neoplasms (Cancer) 01/2020 - 01/2013
1	Carcinoma (Carcinomatosis) 10/2021
1	Macular Degeneration (Age-Related Maculopathy) 11/2020
1	Carcinogenesis 01/2020
1	Colorectal Neoplasms (Colorectal Cancer) 01/2020
1	Dementia (Dementias) 12/2019
1	Heroin Dependence (Heroin Abuse) 01/2018
1	Opioid-Related Disorders (Opiate Addiction) 01/2018
1	Hypoxia (Hypoxemia) 09/2017
1	Synucleinopathies 12/2016
1	Proteostasis Deficiencies 11/2016
1	Alzheimer Disease (Alzheimer's Disease) 09/2014
1	Deafness (Deaf Mutism) 05/2005

Drug/Important Bio-Agent (IBA)

21	polyglutamineIBA 01/2022 - 10/2007
15	Proteins (Proteins, Gene)FDA Link 10/2021 - 10/2007
14	Ataxin-3IBA 12/2021 - 10/2007
5	Deubiquitinating EnzymesIBA 01/2021 - 10/2007
3	Pharmaceutical PreparationsIBA 01/2020 - 11/2016
3	UbiquitinIBA 01/2015 - 08/2010
2	Androgen Receptors (Androgen Receptor)IBA 01/2021 - 01/2018
2	Peptide Hydrolases (Proteases)FDA Link 01/2020 - 01/2014
2	alpha-SynucleinIBA 12/2019 - 12/2016
2	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2015 - 08/2010
2	Cysteine Proteases (Cysteine Protease)IBA 01/2015 - 08/2010
1	Retinaldehyde (Retinal)IBA 11/2020
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2020
1	Serine Proteases (Serine Protease)IBA 01/2020
1	Dopamine (Intropin)FDA LinkGeneric 12/2019
1	Amyloid beta-PeptidesIBA 12/2019
1	Protein Isoforms (Isoforms)IBA 12/2019
1	Fentanyl (Sublimaze)FDA LinkGeneric 01/2018
1	IronIBA 09/2017
1	Chelating AgentsIBA 09/2017
1	LigandsIBA 09/2017
1	AntioxidantsIBA 09/2017
1	Dopamine Agonists (Dopamine Agonist)IBA 12/2016
1	Aripiprazole (Abilify)FDA Link 11/2016
1	Karyopherins (Importin)IBA 08/2015
1	SynucleinsIBA 09/2014
1	tau Proteins (tau Protein)IBA 06/2013
1	Myosin VIIaIBA 05/2005
1	Myosins (Myosin)IBA 05/2005

Therapy/Procedure

1	Therapeutics 11/2016